Significant differences in the analysed patient, tumour or treatment characteristics between patients with the two distinct KRAS mutation subtypes were not observed, except for a higher prevalence of lymphatic invasion within the KRAS‐G12D group. This evidence concerns the gene KRAS and neoplasm.